MLICM
PRLD icon

Metropolitan Life Insurance Company (MetLife)’s Prelude Therapeutics PRLD Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,194
Closed -$99.8K – 2818
2021
Q3 		$99.8K Hold
3,194
– – ﹤0.01% 2513
2021
Q2 		$91.4K Buy
3,194
+315
+11% +$11.2K ﹤0.01% 2613
2021
Q1 		$125K Hold
2,879
– – ﹤0.01% 2325
2020
Q4 		$206K Buy
+2,879
New +$143K ﹤0.01% 1917

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PRLD Position: Q4 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Prelude Therapeutics (PRLD) in Q4 2021, closing a stake of 3,194 shares — an estimated $99.8K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PRLD in Q4 2020 and held it in 4 quarters. The position peaked at $206K in Q4 2020. 75 funds tracked by Wall St. Rank hold PRLD as of Q4 2021.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Prelude Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,194 Prelude Therapeutics shares in Q4 2021, an estimated $99.8K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Prelude Therapeutics in Q4 2020 and held it in 4 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Prelude Therapeutics position peaked at $206K in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2021, filed 15 Feb 2022.